3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
8
Rectal Neoplasms
7
Neoplasm Metastasis
5
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Gallbladder Neoplasms
3
Cholangiocarcinoma
3
Neutropenia
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Lung Neoplasms
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastric Cancer Adenocarcinoma Metastatic
1
First-line Treatment
1
Esophageal Squamous Cell Carcinoma
1
EFS
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Clinical Stage III Gastric Cancer AJCC v8
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Bevacizumab
69
Sorafenib
66
lenvatinib
59
durvalumab
38
sintilimab
33
Nivolumab
32
tislelizumab
28
atezolizumab
28
pembrolizumab
27
Oxaliplatin
26
tremelimumab
23
apatinib
22
Fluorouracil
22
Radiosurgery
20
regorafenib
19
camrelizumab
18
Doxorubicin
18
cabozantinib
16
Leucovorin
16
Capecitabine
16
Radiotherapy
14
Folfox protocol
14
donafenib
13
Gemcitabine
13
Cisplatin
12
toripalimab
11
Erlotinib Hydrochloride
10
spartalizumab
8
anlotinib
8
Neoadjuvant Therapy
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Hepatocellular
×
trifluridine tipiracil drug combination
×
Clear all
NCT07138885
2026-04-29
DRIVE-II
Sun Yat-sen University
Phase 2
Active not recruiting
62 enrolled